Heron Therapeutics | HRTX - Interest Expense On Debt


Heron Therapeutics reported $500K in Interest Expense on Debt for its fiscal quarter ending in September of 2024.





Interest Expense On Debt Change Date
ALKERMES USD 12.28M 7.63M Dec/2025
Alnylam Pharmaceuticals USD 129.34M 84.94M Dec/2025
Amarin USD 3K 5K Dec/2024
ANI Pharmaceuticals USD 4.41M 316K Dec/2025
Anika Therapeutics 189.44M 1.76M Sep/2025
Arrowhead Research USD 22.5M 811K Dec/2025
Eisai JPY 1.43B 12M Dec/2025
Esperion Therapeutics USD 15.08M 1.36M Sep/2024
GlaxoSmithKline GBP 188M 21M Dec/2025
Heron Therapeutics USD 500K 900K Sep/2024
Insmed USD 20.6M 217K Dec/2025
Ligand Pharmaceuticals USD 910K 243K Sep/2025
Merck USD 412M 85M Dec/2025
Nektar Therapeutics USD 6.02M 420K Sep/2024
Neurocrine Biosciences USD 1.1M 0 Mar/2024
Omeros USD 4.05M 5.16M Sep/2024
Pacira USD 3.89M 387K Dec/2025
Regeneron Pharmaceuticals USD 12.2M 7.1M Dec/2025
Roche Holding CHF 304M 7.5M Jun/2025
Sangamo BioSciences 97.56M 11.39M Jun/2025
Surmodics USD 884K 5K Sep/2024
Ultragenyx Pharmaceutical USD 19M 4.85M Dec/2025
Veracyte USD 2K 1000 Dec/2023
Vertex Pharmaceuticals USD 3.3M 0 Dec/2025